Pura Vida Investments LLC grew its holdings in shares of Amarin Co. plc (NASDAQ:AMRN) by 74.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 389,480 shares of the biopharmaceutical company’s stock after purchasing an additional 166,480 shares during the period. Amarin comprises 3.3% of Pura Vida Investments LLC’s holdings, making the stock its 10th largest holding. Pura Vida Investments LLC’s holdings in Amarin were worth $5,301,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Amarin during the 4th quarter worth approximately $34,000. Neuburgh Advisers LLC acquired a new stake in Amarin in the fourth quarter valued at approximately $36,000. Lindbrook Capital LLC acquired a new stake in Amarin in the fourth quarter valued at approximately $40,000. IFP Advisors Inc boosted its position in Amarin by 71.2% in the fourth quarter. IFP Advisors Inc now owns 8,413 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 3,500 shares in the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new stake in Amarin in the fourth quarter valued at approximately $131,000. Hedge funds and other institutional investors own 48.30% of the company’s stock.

A number of analysts have weighed in on the stock. BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research report on Wednesday, February 27th. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Amarin in a research report on Friday, December 7th. Jefferies Financial Group set a $30.00 target price on shares of Amarin and gave the company a “buy” rating in a research report on Thursday, December 20th. HC Wainwright restated a “buy” rating and issued a $51.00 target price on shares of Amarin in a research report on Thursday, January 17th. Finally, Citigroup cut their target price on shares of Amarin to $20.00 in a research report on Tuesday, January 8th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $33.20.

In other news, insider John F. Thero sold 250,000 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.31, for a total transaction of $5,327,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lars Ekman sold 135,377 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.31, for a total transaction of $2,884,883.87. The disclosure for this sale can be found here. Insiders have sold 2,841,072 shares of company stock valued at $49,748,088 in the last ninety days. Insiders own 4.08% of the company’s stock.

AMRN stock opened at $20.33 on Friday. The firm has a market cap of $6.56 billion, a PE ratio of -52.13 and a beta of 1.29. Amarin Co. plc has a 52-week low of $2.35 and a 52-week high of $23.33. The company has a quick ratio of 2.04, a current ratio of 2.40 and a debt-to-equity ratio of 0.35.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.03). The firm had revenue of $77.30 million for the quarter, compared to analysts’ expectations of $73.87 million. The business’s revenue was up 43.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) earnings per share. On average, research analysts predict that Amarin Co. plc will post -0.17 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Amarin Co. plc (AMRN) Holdings Lifted by Pura Vida Investments LLC” was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.mareainformativa.com/news/2019/03/17/amarin-co-plc-amrn-holdings-lifted-by-pura-vida-investments-llc.html.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: What are the benefits of a balanced fund?

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.